Forum für Wissenschaft, Industrie und Wirtschaft

Hauptsponsoren:     3M 


Metformin offers cardio benefits over sulfonylureas in diabetes

A Vanderbilt study examining the impact of the two most commonly prescribed oral diabetes medications on the risk for heart attack, stroke and death has found the drug metformin has benefits over sulfonylurea drugs.

It was important to examine the cardiovascular impact of the more commonly used diabetes drugs after recent controversy surrounded another diabetes medication, rosiglitazone, because it was associated with an increased cardiac risk, said lead author, Christianne L. Roumie, M.D., MPH, assistant professor of Internal Medicine and Pediatrics. Smaller studies pointed to a potential advantage of taking the drug metformin but this study confirms this in a large population.

"We demonstrated that for every 1,000 patients who are using metformin for a year there are two fewer heart attacks, strokes or deaths compared with patients who use sulfonylureas. I think this reinforces the recommendation that metformin should be used as the first medication to treat diabetes," Roumie said.

The researchers looked at the charts of more than 250,000 veterans receiving care in Veterans Health Administration hospitals throughout the United States. The patients were started on oral therapy for their diabetes with either metformin or a sulfonylurea and followed for about a year. Results are in the Nov. 6 issue of Annals of Internal Medicine.

"Both drugs do a good job helping control diabetes and preventing nerve damage and eye disease associated with high sugar levels. We did this study because there was an important knowledge gap about whether metformin was superior to sulfonylureas for prevention of heart disease, stroke and death," said senior author Marie R. Griffin M.D., MPH, professor of Preventive Medicine.

The limitations of the study include that neither patient group was compared with diabetic patients who take no oral medications, and that the veteran patients were mostly men.

Metformin is already the recommended first-line therapy for those needing oral medication to control type 2 diabetes. The most common side effect is stomach upset, which can often be overcome by titrating the dosage up slowly. It has not been recommended that patients with kidney impairment take metformin, so sulfonylureas might be a better choice for those patients.

Roumie said this study suggests it might be prudent to take a second look at those patients who have been taking sulfonylureas to see if a switch to metformin might be recommended.

Craig Boerner | EurekAlert!
Further information:

Further reports about: Internal Medicine Medicine Metformin diabetes drug diabetes medication

More articles from Health and Medicine:

nachricht Fatty liver disease and scarring have strong genetic component
02.10.2015 | University of California - San Diego

nachricht What is the cost of lung cancer in Germany?
01.10.2015 | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Neue Sinumerik-Funktionen steigern Produktivität und Genauigkeit

EMO 2015, Halle 3, Stand E06/F03

  • Antriebsoptimierung aus Teileprogramm ermöglicht höhere Produktivität
  • Automatische Umschaltung der Dynamikwerte für Eilgang und Bearbeitung steigert Qualität...

Im Focus: New Sinumerik features improve productivity and precision

EMO 2015, Hall 3, Booth E06/F03

  • Drive optimization called automatically by the part program boosts productivity
  • Automatically switching the dynamic values to rapid traverse and interpolation...

Im Focus: LZH zeigt additive Fertigung auf der LABVOLUTION

Das Laser Zentrum Hannover e.V. (LZH) zeigt vom 6. bis zum 8. Oktober 2015 auf der LABVOLUTION in Hannover in Halle 9, Stand E67/09 wie laserbasierte Technologien zum Labor der Zukunft beitragen können. Als Teil des Musterlabors smartLAB präsentiert das LZH, wie die additive Fertigung, besser bekannt als 3D-Druck, Versuchsaufbauten flexibler gestalten kann.

Zwölf Partner aus Wissenschaft und Industrie stellen auf der Sonderausstellung smartLAB ein intelligentes und innovatives Musterlabor vor. Teil dieses...

Im Focus: LZH presents additive manufacturing at the LABVOLUTION

The Laser Zentrum Hannover e.V. (LZH) will present how laser-based technologies can contribute to the laboratory of the future at the LABVOLUTION in Hannover in Hall 9, Stand E67/09, from October 6th to 8th, 2015. As a part of the model lab smartLAB, the LZH is showing how additive manufacturing, better known as 3-D printing, can make experimental setups more flexible.

Twelve partners from science and industry are presenting an intelligent and innovative model lab at the special display smartLAB. A part of this intelligent...

Im Focus: New polymer creates safer fuels

Before embarking on a transcontinental journey, jet airplanes fill up with tens of thousands of gallons of fuel. In the event of a crash, such large quantities of fuel increase the severity of an explosion upon impact.

Researchers at Caltech and JPL have discovered a polymeric fuel additive that can reduce the intensity of postimpact explosions that occur during accidents and...

Alle Focus-News des Innovations-reports >>>



im innovations-report
in Kooperation mit academics

Batterietagung im April 2016 in Münster

02.10.2015 | Veranstaltungen

EEHE 2016 – Call for Papers endet am 28.10.2015!

02.10.2015 | Veranstaltungen

HDT-Tagung: 16. Essener Brandschutztage

01.10.2015 | Veranstaltungen

Weitere VideoLinks >>>
Aktuelle Beiträge

Neue Sinumerik-Funktionen steigern Produktivität und Genauigkeit

02.10.2015 | Messenachrichten

Exklusives Design für die Raumbedienung mit den neuen KNX-Tastsensoren

02.10.2015 | Architektur Bauwesen

Schutz aus Glas gegen vielerlei Gefahren: Feuer, Beschuss, Vandalismus und UV-Strahlen

02.10.2015 | Materialwissenschaften